Free
Correspondence  |   October 2017
Clarification: Current Status of Neuromuscular Reversal and Monitoring, Challenges and Opportunities
Author Notes
  • GE Healthcare, Madison, Wisconsin (E.C.H.). Elise.Hyman@ge.com
  • (Accepted for publication June 22, 2017.)
    (Accepted for publication June 22, 2017.)×
Article Information
Correspondence
Correspondence   |   October 2017
Clarification: Current Status of Neuromuscular Reversal and Monitoring, Challenges and Opportunities
Anesthesiology 10 2017, Vol.127, 730. doi:10.1097/ALN.0000000000001795
Anesthesiology 10 2017, Vol.127, 730. doi:10.1097/ALN.0000000000001795
To the Editor:
We are writing to clarify certain statements and information provided in a recent review of neuromuscular reversal and monitoring.1 
The article stated that, “The GE Healthcare E-NMT-01 module was recalled by the FDA in 2014.” To clarify, GE Healthcare initiated the recall voluntarily, and the announcement appeared on the U.S. Food and Drug Administration Web site. This voluntary recall action entailed technology correction and replacement of all modules in the field. It was completed September 28, 2015. The GE Healthcare NeuroMuscular Transmission (NMT) module is commercially available. Additional information is available on the U.S. Food and Drug Administration Web site.2 
The article also incorrectly showed that the GE Healthcare M-NMT module has only a kinemyography sensor and that the E-NMT module has only an electromyography sensor. To clarify, both the M-NMT and E-NMT modules had interchangeable electromyography and kinemyography sensors. The M-NMT module is no longer manufactured and was replaced by the currently available E-NMT module. We emphasize the clinical benefits that can be afforded from routine use of objective neuromuscular monitors.3,4 
Research Support
Support was provided solely from institutional and/or departmental sources.
Competing Interests
Ms. Hyman is employed by GE Healthcare (Chicago, Illinois). Dr. Brull is a shareholder and member of the Board of Directors of Senzime AB (Uppsala, Sweden).
Elise C. Hyman, B.A., Sorin J. Brull, M.D., F.C.A.R.C.S.I. GE Healthcare, Madison, Wisconsin (E.C.H.). Elise.Hyman@ge.com
References
Brull, SJ, Kopman, AF . Current status of neuromuscular reversal and monitoring: Challenges and opportunities. Anesthesiology 2017; 126:173–90 [Article] [PubMed]
U.S. Food and Drug Administration: Class 2 device recall NeuroMuscular Transmission Module, ENMT. Available at: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfres/res.cfm?id=125850. Accessed April 24, 2017
Todd, MM, Hindman, BJ, King, BJ . The implementation of quantitative electromyographic neuromuscular monitoring in an academic anesthesia department. Anesth Analg 2014; 119:323–31 [Article] [PubMed]
Todd, MM, Hindman, BJ . The implementation of quantitative electromyographic neuromuscular monitoring in an academic anesthesia department: Follow-up observations. Anesth Analg 2015; 121:836–8 [Article] [PubMed]